Prescient (ASX: PTX) signs off FY22 with solid progress in clinical pipeline

Highlights

• Prescient significantly expanded its cellular immunotherapy platform in FY22.
• The OmniCAR platform saw substantial business development activities
• The addition of CellPryme-M CAR-T manufacturing enhancement technology was one of the major milestones achieved by the company in FY22

Clinical-stage oncology firm Prescient Therapeutics (ASX:PTX) is working towards expanding its next-generation cell immunotherapy program. At the same time, Prescient is advancing major clinical programs, PTX-100 and PTX-200, in Australia and the US for targeted cancer therapies. Recently, the company published its annual report for the full year ended 30 June 2022.

Let us go through the major highlights in FY22.

Operational updates

The pandemic continued to throw operational challenges in FY22. However, due to the company’s resilient and tenacious management team, Prescient continued to make progress and made solid growth in its clinical pipeline.

Prescient’s research and development efforts and partnerships with world-renowned institutions significantly expanded the company’s cellular immunotherapy platform during the year.

Progress in targeted therapies

PTX-100 demonstrated encouraging results in dose escalation of basket trial. The trial was on gastric, pancreatic, colorectal cancer, myeloma, and T-cell lymphomas. Further, it exhibited an excellent safety profile with no serious adverse event. The study will now focus on T cell lymphomas in an expansion cohort.

PTX-200 is undergoing Phase 1b trial with cytarabine in patients with relapsed and refractory acute myeloid leukaemia (AML). Recently, (after the reporting period), the trial reported a 4th patient with a complete response and an additional patient with a partial response.

Both the therapies were granted Orphan Drug Designation by the US FDA.

Groundbreaking pipeline in personalised medicine

OmniCAR platform

Prescient’s OmniCAR platform witnessed substantial business development activities during the period. It is a flexible, modular Chimeric Antigen Receptor (CAR) platform with the potential to address problems of conventional CAR-T technologies.

Partnership opportunities – The OmniCAR platform is drawing interest from large pharmaceutical and small biotechnology companies in the CAR-T sector. The company expects these experiences to lead to several new partnership opportunities in the industry.

CellPryme-M

The addition of Prescient’s CellPryme-M CAR-T manufacturing enhancement technology was one of the major milestones during the period. It improves the next-generation OmniCAR platform by addressing key problems faced by several approved and emerging cell therapies. Further, it produces more favourable cell phenotypes that drive superior clinical outcomes.

The technology was developed in collaboration with globally acclaimed Peter MacCallum Cancer Centre (Peter Mac) in Melbourne.

CellPryme-M is ready for clinical testing with GMP materials available to partners.

Capital position – Prescient is sufficiently funded to progress towards several significant milestones. It has cash reserves of over AU$11 million.

Bottom line

To wrap up, Prescient ended the year with a pipeline of unique cancer programs swiftly progressing towards different value-adding milestones. The business is in a good financial position and is well funded to advance its development programs.

Also read: Prescient (ASX: PTX) makes ‘solid progress on all fronts’ in June quarter

To know more about Prescient Therapeutics Limited, click here. Also, to stay updated with PTX company activities and announcements, please update your details on their investor centre.